IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

Patent Application No. 10/573,274

Applicant: Yanagisawa et al.

Filed: March 23, 2006

TC/AU: Unassigned

Examiner: Unassigned

Docket No.: 251371 (Client Reference No. 201257)

Customer No.: 23460

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of Yanagisawa et al. Application No. 10/573,274

	of a fir after th	rst Office Action on the merits; or (d) before the mailing of a first Office Action he filing of a request for continued examination under 37 CFR 1.114 .					
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:						
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).					
	\Box	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).					
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowan under 37 CFR 1.311, or an action that otherwise closes prosecution in the application and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).						
	payme contain 37 CF: \$180 a NOTE: May 29	he mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before nt of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of set forth in 37 CFR 1.17(p) (see "Fees" below). This is for original applications except applications for a design patent, filed on or after ,2000, wherein a paper containing only an Information Disclosure Statement in compliance CFR 1.97 and 1.98 is being filed.					
Copie	s of the	References					
	Copies herewi	s of all of the references listed on the enclosed Form 1449 are enclosed th.					
\boxtimes	Form 1	of U.S. patents and patent applications that are listed on the accompanying 1449 are not enclosed herewith. Copies of other references identified on the panying Form 1449 are enclosed herewith.					
⊠	relevar an Eng action degree	ed to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or dish-language abstract, or an English-language version of the search report or by a foreign patent office in a counterpart foreign application indicating the of relevance found by the foreign office is being submitted in lieu of a concise ation of the relevance pursuant to 37 CFR 1.98(a)(3).					
\boxtimes	A copy	of the International Search Report is enclosed herewith.					
	parent	ferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were ed at that time. Accordingly, additional copies of the references are not					

In re Appln. of Yanagisawa et al. Application No. 10/573,274

submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLI	CATIONS	STATUS (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
1.					
2.					
3.					

3.					
State	ment under 37 CFR	1.97(e)			
	Information Disclo foreign patent offic	ereby states that each ite sure Statement was first e in a counterpart foreig filing of the Information	cited in any co n patent applic	mmunication	n from a
	Information Disclo office in a counterp undersigned after n Information Disclo	ereby states that no item sure Statement was cited art foreign patent applic alking reasonable inquir sure Statement was know re than three months print.	l in a communi ation, and, to to y, no item of in yn to any indiv	cation from a he knowledge oformation co vidual designa	a foreign patent e of the ontained in the ated in
State	ment under 37 CFR	1.704(d)			
	Information Disclo office in a counterp any individual desi	ereby states that each ite sure Statement was cited art application and that t gnated in 37 CFR 1.56(c Disclosure Statement.	in a communi	ication from a	a foreign patent t received by
Fees					
\boxtimes	No fee is owed by the Charge Deposit Ac (A duplicate copy of	he applicant(s). count No. 12-1216 in the f this communication is	e amount of \$1 enclosed for the	80.00 (37 CF	FR 1.17(p)).

3

In re Appln. of Yanagisawa et al. Application No. 10/573,274

Authorization to Charge Additional Fees

 \boxtimes

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

M

Credit Account No. 12-1216. Refund

> John Kilyk, J., Reg. No. 30,763 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900

180 North Stetson Avenue Chicago, Illinois 60601-6780 (312) 616-5600 (telephone)

(312) 616-5700 (facsimile)

Date: June 23, 2006

IDS (Revised 2005 08 01)

Please type a plus sign (+) inside this box ->	F

Substitute for form 1449A/B/PTO

INEC	DRMATION I	חופו	'I OSLIDE	Filing Date	March 23, 2006	
				First Named Inventor	Yanagisawa et al.	
SIA	TEMENT BY	AP	PLICANT	Group Art Unit	Unassigned	
	(Use as many sheet	s as ne	cessarv)	Examiner Name	Unassigned	
			••	Attorney Docket Number	251371	
Sheet	1	of	1	Client Reference No.	201257	

Application Number

Complete if Known

10/573,274

U.S. PATENT DOCUMENTS								
Examiner Initials		U.S. Patent Do	cument		1			
		Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
			+		 			
	\vdash		+	***************************************	-			
			 					
			-					

		Foreign Patent Document					Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
	AA	JP	10-310524	Α	SANKYO CO. LTD.	Nov. 24, 1998		X
	ΑВ	JP	2002-255813	А	FUSO PHARMACEUTICAL INDUSTRIES, LTD.	Sep. 11, 2002		X⁺
	AC	wo	02/083127	A1	Miyata	Oct. 24, 2002		_ X*

Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	lation
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**
	AD	DANNLEY et al., Canadian Journal of Chemistry, 43: 2610-2612 (1965)		
	AE	KIM et al., Korean Journal of Medicinal Chemistry, 5(1): 28-37 (1995)		
	AF	LEWIS et al., The New England Journal of Medicine, 329(20): 1456-1462 (Nov. 11, 1993)		I
	AG	UENO, Japanese Journal of Clinical Medicine (Nippon Rinsho), 60(10): 1999-2004 (Oct. 1, 2002)		X⁺
	AH	YAMAMOTO et al., Chem. Pharm. Bull., 46(11): 1716-1723 (Nov. 1998)		

Examiner Signature	/Niloofar Rahmani/	Date Considered	04/17/2008	

A concise statement of relevance is being submitted in Issu of a translation. 37 CFR 1.99(a)(3).
A Rengish-Inaquage equivalent/patent or an English-Inaquage abertact, or an English-Inaquage version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).